A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation (LIBREXIA-AF)

In by Hannah Schaffner

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation (LIBREXIA-AF)

  • Hidden
  • This field is for validation purposes and should be left unchanged.

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non- central nervous system (CNS) systemic embolism.

clinicaltrials.gov

Eligibility

Inclusion Criteria
  1. Minimum age of 18 years
  2. Medically stable and appropriate for chronic antithrombotic treatment
  3. Atrial fibrillation eligible to receive anticoagulation
  4. Participant must satisfy one or both of the following categories of risk factors (a or b): a) one or more of the following risk factors: i) age greater than or equal to 75 years, ii) history of a clinical symptomatic stroke. b) two or more of the following risk factors: i) age between 65 and 74 years, ii) hypertension, iii) diabetes mellitus, iv) atherosclerotic vascular disease, v) heart failure
Exclusion Criteria
  1. Hemodynamically significant valve disease or those with valve disease that will potentially require surgical valve replacement during the study
  2. Any condition other than AF that requires chronic anticoagulation
Back to Current Studies